Three trials have backed the measurement of secretory phospholipase A2 (sPLA2) as a means to predict heart disease patients' risk of adverse events. Much of the research was conducted by Aterovax, an emerging French company developing a blood test for sPLA2. The first trial focussed ...
Please Login to read the full article.
